Shares of Mylan N.V. (NASDAQ:MYL) have been assigned an average rating of “Buy” from the twenty-seven analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, twelve have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $47.83.

A number of research analysts have recently weighed in on MYL shares. Wells Fargo & Company reissued a “market perform” rating and set a $40.00 target price on shares of Mylan N.V. in a research report on Friday, April 14th. Royal Bank Of Canada reissued a “sector perform” rating and set a $46.00 target price (down from $48.00) on shares of Mylan N.V. in a research report on Monday, April 17th. Deutsche Bank AG reduced their target price on shares of Mylan N.V. from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, April 18th. BMO Capital Markets started coverage on shares of Mylan N.V. in a research report on Monday, May 1st. They set an “outperform” rating and a $50.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Mylan N.V. from a “hold” rating to a “sell” rating in a research report on Monday, May 15th.

In related news, insider Anthony Mauro sold 10,000 shares of Mylan N.V. stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider now directly owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Rajiv Malik sold 25,000 shares of Mylan N.V. stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the transaction, the president now directly owns 799,855 shares of the company’s stock, valued at $31,994,200. The disclosure for this sale can be found here. Company insiders own 0.69% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. First Personal Financial Services boosted its position in shares of Mylan N.V. by 33.2% in the first quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock valued at $107,000 after buying an additional 681 shares during the period. Global X Management Co. LLC boosted its position in Mylan N.V. by 91.6% in the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after buying an additional 1,441 shares during the last quarter. Ropes Wealth Advisors LLC bought a new position in Mylan N.V. during the first quarter valued at $136,000. Oakworth Capital Inc. boosted its position in Mylan N.V. by 30.7% in the first quarter. Oakworth Capital Inc. now owns 4,255 shares of the company’s stock valued at $166,000 after buying an additional 1,000 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new position in Mylan N.V. during the first quarter valued at $188,000. 70.19% of the stock is owned by institutional investors.

Mylan N.V. (NASDAQ MYL) traded down 4.37% during trading on Friday, reaching $30.88. The company had a trading volume of 11,080,764 shares. The company has a market capitalization of $16.56 billion, a price-to-earnings ratio of 24.96 and a beta of 1.27. Mylan N.V. has a one year low of $29.58 and a one year high of $49.42. The company has a 50-day moving average price of $37.34 and a 200 day moving average price of $39.01.

Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.18 by $0.08. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3 billion. During the same period in the previous year, the company posted $1.16 earnings per share. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. Analysts expect that Mylan N.V. will post $4.68 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/mylan-n-v-myl-receives-average-rating-of-buy-from-analysts/1478942.html.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.